Longeveron named XPRIZE Healthspan Milestone 2 awardee with $1 million award

Longeveron/Laromestrocel (Lomecel-B)

Longeveron was selected from over 600 applicants as a Milestone 2 finalist in the $101M XPRIZE Healthspan competition, receiving $1M for clinical trials. The selection recognizes published clinical data demonstrating laromestrocel's ability to improve walking distance in aging-related frailty. The company competes for a grand prize of up to $81M through 2029.

• Selected from over 600 global submissions based on published data
• $1M supports clinical trial participation through end of 2029
• Recognition tied to demonstrated improvement in aging-related frailty markers
• Competing for grand prize up to $81M for healthspan restoration in aging adults